QR Code

Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case series is unique in its focus on the intracran...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Illaa Smesseim, MD, Tijmen van der Wel, MD, Sushil K. Badrising, MD, PhD
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2024-12-01
Rangatū:JTO Clinical and Research Reports
Ngā marau:
RET
Selpercatinib
Non–small-cell lung carcinoma
RET fusion
NSCLC
Case Report
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2666364324001000
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite